Flow diversion for posterior circulation aneurysms: a retrospective single-center 10-year experience
Neuroradiology · 16.11.2026
DOI: 10.1007/s00234-026-04281-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuroradiology, online erschienen am 16.11.2026. Verfasst von Baptiste Donnard und 10 weiteren Autor:innen. Beteiligte Einrichtung: Diagnostic and Interventional Neuroradiology Department, Centre Hospitalier Universitaire de Tours, Tours, France. baptiste.donnard@wanadoo.fr. Die Arbeit nennt 51 Literaturangaben.
Abstract (Originalsprache)
Purpose
Flow diverter stents (FDs) have expanded treatment options for posterior circulation aneurysms, but their use remains controversial due to a higher risk of ischemic complications. Dual antiplatelet therapy (DAPT) is mandatory after FDs implantation; however, clopidogrel shows variable effectiveness. Ticagrelor may represent an alternative, though data in posterior circulation flow diversion are limited. We report a single-center, 10-year experience using ticagrelor-based DAPT.
Methods
We retrospectively reviewed consecutive patients treated with FDs for posterior circulation aneurysms between January 2014 and December 2024 under ticagrelor and aspirin. Previously ruptured aneurysms retreated with FDs following initial management were eligible. No aneurysm was treated during the acute phase of rupture. The primary endpoint was adequate occlusion (OKM C–D) at last imaging follow-up.
Results
Fifty-four patients were included, with 36 aneurysms (67%) treated as first-line therapy. Mean age was 56 ± 11 years. Aneurysms were most commonly located at the basilar tip (42%) with a median size of 6.5 mm (IQR 4–11). Imaging follow-up was available in 52 patients (96%) with a median duration of 34 months (IQR 19.0-49.5). Adequate occlusion (OKM C-D) was achieved in 63% at 6 months and 81% at last follow-up. Ischemic complications occurred in 17% of patients, including 11% symptomatic events, mainly in territories of jailed posterior cerebral arteries. One symptomatic event was fatal (2%). No hemorrhagic complications or delayed ruptures occurred.
Conclusion
Flow diversion under ticagrelor-aspirin DAPT achieved adequate occlusion in 81%. Symptomatic ischemic complications occurred in 11% of patients, including one fatal event, predominantly following basilar tip aneurysm treatment. Four of the six symptomatic events occurred within ten days of planned ticagrelor discontinuation, raising questions about the optimal duration of antiplatelet therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Diagnostic and Interventional Neuroradiology Department, Centre Hospitalier Universitaire de Tours, Tours, France. baptiste.donnard@wanadoo.fr.
- Diagnostic and Interventional Neuroradiology Department, Centre Hospitalier Universitaire de Tours, Tours, France.
- Institute for Diagnostic and Interventional Neuroradiology, University Hospital of Bern, Bern, Switzerland.
- Department of neurology, Centre Hospitalier Universitaire de Tours, Tours, France.
ORCID-Profile: Baptiste Donnard, Heloise Ifergan
Zitieren
APA
Donnard, B., Boulouis, G., Bala, F., Ifergan, H., Barrot, V., Beaufort, Q., Kaesmacher, J., Hoche, C., Bibi, R., Herbreteau, D., & Janot, K. (2026). Flow diversion for posterior circulation aneurysms: a retrospective single-center 10-year experience. Neuroradiology. https://doi.org/10.1007/s00234-026-04281-5
Vancouver
Donnard B, Boulouis G, Bala F, Ifergan H, Barrot V, Beaufort Q, et al. Flow diversion for posterior circulation aneurysms: a retrospective single-center 10-year experience. Neuroradiology. 2026. doi:10.1007/s00234-026-04281-5
BibTeX
@article{Donnard2026,
author = {Donnard, Baptiste and Boulouis, Gregoire and Bala, Fouzi and Ifergan, Heloise and Barrot, Valere and Beaufort, Quentin and Kaesmacher, Johannes and Hoche, Clemence and Bibi, Richard and Herbreteau, Denis and Janot, Kevin},
title = {Flow diversion for posterior circulation aneurysms: a retrospective single-center 10-year experience},
journal = {Neuroradiology},
year = {2026},
doi = {10.1007/s00234-026-04281-5}
}
EUVIMED